Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster
Author(s) -
Vicki A. Morrison,
Michael N. Oxman,
Myron J. Levin,
Kenneth E. Schmader,
John Guatelli,
Robert F. Betts,
Larry Gelb,
Constance T. Pachucki,
Susan Keay,
Barbara E. Menzies,
Marie R. Griffin,
Carol A. Kauffman,
Adriana Marques,
John Toney,
Michael S. Simberkoff,
Richard Serrao,
Robert D. Arbeit,
John W. Gnann,
Richard N. Greenberg,
Mark Holodniy,
Wendy A. Keitel,
ShingShing Yeh,
Larry E. Davis,
George Crawford,
Kathy M. Neuzil,
Gary R. Johnson,
Jane H. Zhang,
Rith Harbecke,
Ivan S. F. Chan,
Paul M. Keller,
Heather Williams,
Kathy D. Boardman,
Jeffrey L. Silber,
Paula W. Annunziato
Publication year - 2013
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jit182
Subject(s) - shingles , medicine , veterans affairs , placebo , varicella zoster virus , virology , virus , alternative medicine , pathology
After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom